Breakthrough in Melanoma Treatment: Genetic Engineering of T Cells Shows Promise

Recent research has presented a fresh understanding of melanomas, a type of skin cancer, using genetic engineering of T cells to target the ganglioside GD2, a tumor-associated antigen found in a high proportion of melanoma cells. The study, published in Clinical Cancer Research, reveals that genetically engineered T cells can produce antitumor effector cells that bypass tumor immune escape mechanisms. These cells, modified to express a chimeric antigen receptor (CAR) specific to GD2, demonstrated antimelanoma activity in vitro and in a murine xenograft model.

Key Takeaways:

• Genetic engineering of human T lymphocytes to express tumor-directed chimeric antigen receptors (CAR) can produce antitumor effector cells that bypass tumor immune escape mechanisms.
• The transgenic receptors can be directed to tumor-associated antigens that are not protein-derived, such as the ganglioside GD2, which is expressed in a high proportion of melanoma cells.
• The researchers generated chimeric T cells specific for GD2 by joining an extracellular antigen-binding domain derived from the GD2-specific antibody sc14.G2a to cytoplasmic signaling domains derived from the T-cell receptor zeta-chain.
• The CAR-GD2 T lymphocytes incorporating the CD28 and OX40 endodomains secreted significant levels of cytokines in a pattern comparable with the cytokine response obtained by engagement of the native CD3 receptor.
• The CAR-T cells had antimelanoma activity in vitro and in the xenograft model, increasing the survival of tumor-bearing animals.
• The study suggests that redirecting human T lymphocytes to the tumor-associated ganglioside GD2 generates effector cells with antimelanoma activity that should be testable in subjects with disease.
• The researchers, led by E. Yvon and colleagues from Baylor College of Medicine, propose that this approach could potentially lead to a breakthrough in melanoma treatment.

Statistics:

• The study demonstrated antimelanoma activity in vitro and in a murine xenograft model.
• The CAR-GD2 T lymphocytes secreted significant levels of cytokines, comparable to the response obtained by engagement of the native CD3 receptor.
• The survival of tumor-bearing animals was increased in the xenograft model.
• The study's findings suggest a promising approach to melanoma treatment.

Sources:

• Yvon et al. (2009). Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clinical Cancer Research, 15(18), 5852-5860.
• Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030 USA.
• American Association Cancer Research, 615 Chestnut St., 17TH Floor, Philadelphia, PA 19106-4404, USA.